Electrophysiological effects of WAY 100635, a new 5-HT1A receptor antagonist, on dorsal raphe nucleus serotoninergic neurones and CA1 pyramidal cells in vitro

R Corradetti; A M Pugliese; E Le Poul; N Laaris; M Hamon; L Lanfumey

Electrophysiological effects of WAY 100635, a new 5-HT1A receptor antagonist, on dorsal raphe nucleus serotoninergic neurones and CA1 pyramidal cells in vitro

Acta Physiol Hung. 1996;84(4):407-9.

Authors

R Corradetti¹, A M Pugliese, E Le Poul, N Laaris, M Hamon, L Lanfumey

Affiliation

¹ Department of Preclinical and Clinical Pharmacology, University of Florence, Firenze, Italy.

PMID: 9328615

Abstract

The novel 5-HT1A receptor antagonist WAY 100635 [(N-(2-(-4(2-metoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyc lohexane carboxamide)] has been tested on 5-HT1A receptor-mediated inhibition of firing and intracellularly recorded hyperpolarisation of serotoninergic cells of the dorsal raphe nucleus (DRN) and on hyperpolarisation of hippocampal CA1 pyramidal cells. WAY 100635 selectively blocked 5-HT1A receptor-mediated responses of 5-HT, 8-OH-DPAT, lesopitron and 5-CT. The antagonism of the hyperpolarisation elicited by 5-CT was competitive in the DRN and non competitive in CA1, probably because of the existence of a 5-HT1A receptor reserve in serotoninergic cells of DRN.

MeSH terms

Animals
Electrophysiology
Hippocampus / cytology
Hippocampus / drug effects
Hippocampus / physiology
In Vitro Techniques
Membrane Potentials / drug effects
Neurons / drug effects
Neurons / metabolism*
Piperazines / pharmacology*
Pyramidal Cells / drug effects
Pyramidal Cells / metabolism*
Pyridines / pharmacology*
Raphe Nuclei / cytology*
Raphe Nuclei / drug effects
Rats
Serotonin Antagonists / pharmacology*

Substances

Piperazines
Pyridines
Serotonin Antagonists
N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide